


Development of a HNP-2006 contrast agent with improved safety



OTHERS	Phase 2
Product Type	New Chemical Entity
Indication	To(early) detection of tumor, abnormal vessel, nerve system or organs.
Target	Contrast enhancement for brain and spin magnetic resonance imaging, for magnetic resonance angiography
MoA(Mechanism of Action)	By generating high-frequency waves in a magnetic field environment, the hydrogen atom nuclei in the body parts are resonated, and the difference in signals from each tissue is converted into digital information and reconstructed through a computer for imaging.
Competitiveness	<ul style="list-style-type: none"> ① Stable structure for reducing release of free gadolinium. ② The achiral structure of HNP-2006 offers a simple low-cost manufacturing method compared to other chiral MRI agents. ③ The patent was terminated in all other commercial MRI agents. ④ Improved visualization compared to commercial MRI agents.
Development Stage	Phase 2
Route of Administration	Intravenous Injection